Market Cap 19.81B
Revenue (ttm) 4.24B
Net Income (ttm) 32.61M
EPS (ttm) N/A
PE Ratio 18.93
Forward PE 17.17
Profit Margin 0.77%
Debt to Equity Ratio 0.00
Volume 490,600
Avg Vol 2,436,794
Day's Range N/A - N/A
Shares Out 196.32M
Stochastic %K 70%
Beta 0.81
Analysts Sell
Price Target $101.00

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:02 PM
Actionable Trade Alert for $INCY: Market Context: $INCY closed at $100.44, currently trading in a neutral range with an RSI of 49.96, indicating no overbought or oversold conditions. The price is slightly below the 30-day moving average (MA30) of 101.16 but above the 50-day moving average (MA50) of 98.73, suggesting potential bullish momentum. Directional Bias: The price is within the 60-day high of 109.28 and low of 82.82, indicating a range-bound market. A break above the MA30 could signal upward movement. Trade Plan: - Suggested Entry: $101.00 (break above MA30) - Stop Loss: $97.50 (below MA50) - Take Profit Targets: 1. $105.00 (4% gain) 2. $108.00 (6.9% gain) 3. $117.00 (16.5% gain) This plan offers a potential ROI of over 17% on the third target. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 23 at 10:19 PM
Commercial-stage oncology focused bio valuation related data points for those with market caps north of $1.5B $SNDX is up sharply the last 5 months. In early August 2025, investors could buy SNDX for $10/share. Since the ASH presentations, the market appears more confident longer-term revenue estimates are attainable. All the same, at $22 a share SNDX still trades at meaningfully lower multiples of projected revenues than the others in this specific peer group. $INCY could, in theory, buy SNDX for 4.0X FY29 revenue estimates consistent with peer M&A revenue multiples paid. Should INCY maintain a 4.2X FY29 revenue multiple the acquisition would, again in theory, be accretive to INCY shareholders. $LEGN valuation continues to suffer in light of $JNJ recent combo drug data that meaningfully outperformed Carvykti in R/R MM. It's been 2 weeks & we're unaware of any reduction in LEGN analyst projections (we could be wrong). This is not investment advice (especially LEGN). $XBI
1 · Reply
billyl
billyl Dec. 22 at 9:39 PM
$INCY finally have a cure after being fked in the axx for so long by the market makers on this stock for so long… https://client.schwab.com/app/research/#/stocks/news/INCY
0 · Reply
Jack_SG
Jack_SG Dec. 22 at 12:05 PM
$INCY https://www.moomoo.com/news/post/63157927?ns_stock_id=206483&report_type=stock&report_id=54527045&main_broker=WwogIDEwMDgKXQ==&sg_cid=102974120&skintype=3&src=2&stock_news_tab=news&futusource=news_stock_stockpagenews&client_hour_clock=24&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A63157927%22%2C%22invite%22%3A102974120%7D&data_ticket=f2be62e716b3928dd3d46e6d5ee73116
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Dec. 21 at 3:45 PM
$INCY $19.1B mc $XBI / $IBB really taking the lead in this space following this weeks accumulation week and recapturing of key $100 level off the rising 10-week SMA. Working its way out of a 7-year base - Humongous ramp in Pct of All Funds over the past two quarters. TrendEdge.app/asset/INCY
0 · Reply
Doozio
Doozio Dec. 21 at 12:06 AM
$INCY if only they wud give YO a 🪧. MAMA said listen to yo Baker $BROS Chop chop poppa huckleberry is coming to TOWN 🐒🍌🧠⏰♾️
0 · Reply
1iquid
1iquid Dec. 20 at 6:35 PM
OptionWizards Tip (education only): Roll positions ahead of earnings on INCY, TPR, or DGX to manage risk from potential volatility jumps. $INCY $TPR $DGX Not financial advice.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 20 at 5:15 PM
$SNDX 's Revuforj is as synergistic a fit into INCY's existing hematology portfolio as exists in commercial-stage bio today. Seriously, we cannot find a better candidate so if we are missing one please share in the comments. Attached is a snapshot of $INCY revenues for the last 8 quarters with Revuforj included above for perspective. 90% of Revuforj sales to date have been in the KMT2A population (per SNDX Q325 IR deck). Hence if the mNPM1 TAM is ~2.0X higher & if Revuforj's better ORR profile carries the day (v Ziftomenib) then Revuforj would quickly become INCY's 3rd or 4th best selling product almost overnight. These are 2 BIG IFs. Obviously, Revuforj can only disappoint as maybe KURA's Ziftomenib better side effect profile carries the day. We will only know with certainty over time. Why SNDX waits is beyond us. Eventually, there will be disappointing news (a revenue miss, adverse event, mfg issues, reimbursement etc) This is not investment advice. $XBI $IBB
2 · Reply
GorillaTrades
GorillaTrades Dec. 19 at 8:05 PM
op 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Incyte $INCY +6.7%, HEICO $HEI +5.8%, and Tesla $TSLA +5.2%
0 · Reply
ortega1963
ortega1963 Dec. 19 at 6:41 PM
$INCY bot 101 $
0 · Reply
Latest News on INCY
Incyte to Present at Upcoming Investor Conference

Dec 18, 2025, 8:00 AM EST - 7 days ago

Incyte to Present at Upcoming Investor Conference


Incyte Announces Change to its Board of Directors

Dec 12, 2025, 8:30 AM EST - 13 days ago

Incyte Announces Change to its Board of Directors


Incyte: Buy At This Inflection Point

Dec 6, 2025, 9:00 AM EST - 19 days ago

Incyte: Buy At This Inflection Point


Incyte: This Profitable Biotech Trades Like A Melting Iceberg

Nov 27, 2025, 4:09 AM EST - 4 weeks ago

Incyte: This Profitable Biotech Trades Like A Melting Iceberg


Incyte: Riding Jakafi, Bracing For Generic Headwinds

Nov 27, 2025, 1:11 AM EST - 4 weeks ago

Incyte: Riding Jakafi, Bracing For Generic Headwinds


Incyte to Present at Upcoming Investor Conferences

Nov 19, 2025, 8:00 AM EST - 5 weeks ago

Incyte to Present at Upcoming Investor Conferences


Top Biotech Stocks Riding The Rally

Nov 4, 2025, 3:15 PM EST - 7 weeks ago

Top Biotech Stocks Riding The Rally

CTMX GRAL GRFS


Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 11:41 AM EDT - 2 months ago

Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript


Incyte: Strong Growth, Margin Expansion, And Low Valuation

Oct 21, 2025, 11:13 PM EDT - 2 months ago

Incyte: Strong Growth, Margin Expansion, And Low Valuation


3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 2 months ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY SNDX XBI


Incyte to Report Third Quarter Financial Results

Oct 8, 2025, 8:00 AM EDT - 2 months ago

Incyte to Report Third Quarter Financial Results


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 3 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB MLYS SNDX TVTX


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:02 PM
Actionable Trade Alert for $INCY: Market Context: $INCY closed at $100.44, currently trading in a neutral range with an RSI of 49.96, indicating no overbought or oversold conditions. The price is slightly below the 30-day moving average (MA30) of 101.16 but above the 50-day moving average (MA50) of 98.73, suggesting potential bullish momentum. Directional Bias: The price is within the 60-day high of 109.28 and low of 82.82, indicating a range-bound market. A break above the MA30 could signal upward movement. Trade Plan: - Suggested Entry: $101.00 (break above MA30) - Stop Loss: $97.50 (below MA50) - Take Profit Targets: 1. $105.00 (4% gain) 2. $108.00 (6.9% gain) 3. $117.00 (16.5% gain) This plan offers a potential ROI of over 17% on the third target. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 23 at 10:19 PM
Commercial-stage oncology focused bio valuation related data points for those with market caps north of $1.5B $SNDX is up sharply the last 5 months. In early August 2025, investors could buy SNDX for $10/share. Since the ASH presentations, the market appears more confident longer-term revenue estimates are attainable. All the same, at $22 a share SNDX still trades at meaningfully lower multiples of projected revenues than the others in this specific peer group. $INCY could, in theory, buy SNDX for 4.0X FY29 revenue estimates consistent with peer M&A revenue multiples paid. Should INCY maintain a 4.2X FY29 revenue multiple the acquisition would, again in theory, be accretive to INCY shareholders. $LEGN valuation continues to suffer in light of $JNJ recent combo drug data that meaningfully outperformed Carvykti in R/R MM. It's been 2 weeks & we're unaware of any reduction in LEGN analyst projections (we could be wrong). This is not investment advice (especially LEGN). $XBI
1 · Reply
billyl
billyl Dec. 22 at 9:39 PM
$INCY finally have a cure after being fked in the axx for so long by the market makers on this stock for so long… https://client.schwab.com/app/research/#/stocks/news/INCY
0 · Reply
Jack_SG
Jack_SG Dec. 22 at 12:05 PM
$INCY https://www.moomoo.com/news/post/63157927?ns_stock_id=206483&report_type=stock&report_id=54527045&main_broker=WwogIDEwMDgKXQ==&sg_cid=102974120&skintype=3&src=2&stock_news_tab=news&futusource=news_stock_stockpagenews&client_hour_clock=24&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A63157927%22%2C%22invite%22%3A102974120%7D&data_ticket=f2be62e716b3928dd3d46e6d5ee73116
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Dec. 21 at 3:45 PM
$INCY $19.1B mc $XBI / $IBB really taking the lead in this space following this weeks accumulation week and recapturing of key $100 level off the rising 10-week SMA. Working its way out of a 7-year base - Humongous ramp in Pct of All Funds over the past two quarters. TrendEdge.app/asset/INCY
0 · Reply
Doozio
Doozio Dec. 21 at 12:06 AM
$INCY if only they wud give YO a 🪧. MAMA said listen to yo Baker $BROS Chop chop poppa huckleberry is coming to TOWN 🐒🍌🧠⏰♾️
0 · Reply
1iquid
1iquid Dec. 20 at 6:35 PM
OptionWizards Tip (education only): Roll positions ahead of earnings on INCY, TPR, or DGX to manage risk from potential volatility jumps. $INCY $TPR $DGX Not financial advice.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 20 at 5:15 PM
$SNDX 's Revuforj is as synergistic a fit into INCY's existing hematology portfolio as exists in commercial-stage bio today. Seriously, we cannot find a better candidate so if we are missing one please share in the comments. Attached is a snapshot of $INCY revenues for the last 8 quarters with Revuforj included above for perspective. 90% of Revuforj sales to date have been in the KMT2A population (per SNDX Q325 IR deck). Hence if the mNPM1 TAM is ~2.0X higher & if Revuforj's better ORR profile carries the day (v Ziftomenib) then Revuforj would quickly become INCY's 3rd or 4th best selling product almost overnight. These are 2 BIG IFs. Obviously, Revuforj can only disappoint as maybe KURA's Ziftomenib better side effect profile carries the day. We will only know with certainty over time. Why SNDX waits is beyond us. Eventually, there will be disappointing news (a revenue miss, adverse event, mfg issues, reimbursement etc) This is not investment advice. $XBI $IBB
2 · Reply
GorillaTrades
GorillaTrades Dec. 19 at 8:05 PM
op 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Incyte $INCY +6.7%, HEICO $HEI +5.8%, and Tesla $TSLA +5.2%
0 · Reply
ortega1963
ortega1963 Dec. 19 at 6:41 PM
$INCY bot 101 $
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:57 PM
Actionable Trade Alert for $INCY: Market Context: $INCY is currently trading at $97.31, showing a potential reversal opportunity given the RSI at 32.92, indicating oversold conditions. The price is near the 60D low of $81.09, suggesting a support zone. Directional Bias: The bearish momentum appears to be waning, as the stock is below the MA30 (101.85) but above the MA50 (97.42), indicating potential for a rebound. The ATR of 3.18 suggests moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $97.50 - Stop Loss: $93.00 (4.57% risk) - Take Profit Targets: 1. $102.00 (4.85% gain) 2. $105.00 (7.72% gain) 3. $114.00 (17.05% gain) With the potential for a 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor price action closely for confirmation of the reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 19 at 3:49 PM
It appears the $FOLD M&A exit at an enterprise value of $4.8B was priced @ 0.36X cumulative 10-year analyst consensus revenue estimates. This is consistent with 90% of peer commercial-stage (oncology & non-oncology) M&A between 0.30X & 0.40X. $SNDX continues to be our top M&A candidate with $INCY. At the moment SNDX trades at 0.15X 10-year analyst consensus & those SNDX revenues generate the highest gross profit margin of any the M&A peer group. The attachment is our tracker of historical commercial-stage M&A going back to 1/1/2013. Recalculate the revenue multiples paid for yourself. Our other M&A picks in FY2026 include $URGN & $IOVA Just remember we are usually wrong when we speculate. If we were that good we would not be posting on STs. This is for entertainment purposes only. This is not investment advice. Happy holidays!
3 · Reply
2_logs_higher
2_logs_higher Dec. 19 at 3:16 PM
$AGEN & $INCY But according to Agen, what does INCY know?
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 17 at 11:57 PM
Our model calculating the total NPV (net present value) of the $INCY payments due $SNDX thru FY38 under the 50/50 Niktimvo partnership @ $1.959B if (THESE ARE HUGE IFs); 1. Niktimvo US sales forecast data points cited by $RPRX in their 11/2024 investor deck are credible ($350MM for a 13.8% royalty yields a "low double digits" IRR & full repayment @ 2.35X by FY38). Our forecast's IRR = 11.2% 2. 5-year Niktimvo US sales consensus was up 96% from RPRX's original 11/2024 forecast (#1 above), as RPRX noted in their 9/11/2025 investor deck 3. Net collaboration revenue (INCY payment) due SNDX averages 40% of Niktimvo US sales per #2 above (actual Q325 = ~30%) beginning in FY26 4. INCY’s discount rate = 14% (sec .gov has been spotty but peer acquirer's cost of capital range 11-14%). At 12%, the total NPV = ~$2.2B This exercise does not consider SNDX Niktimvo ex-US value (mid-teen royalty) nor Revuforj Of course we c/b wrong. This is for entertainment purposes & not investment advice Genuine pushback?
3 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 17 at 4:55 PM
0 · Reply
dumb_money_wins_again
dumb_money_wins_again Dec. 17 at 5:59 AM
$INCY I've literally never been more bullish on a stock in my life. I would take out a fkn second mortgage and sell all my belongings to go all in on $INCY rn. so tempted to liquidate all my positions just to send it on $INCY. YES I'M THAT SURE.
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:43 AM
Actionable Trade Alert for $INCY: Market Context: $INCY is currently trading at $97.03, with a Relative Strength Index (RSI) of 30.0, indicating that the stock is oversold. The 60-day high of $109.28 suggests potential upside, while the low of $81.09 provides a solid support level. Directional Bias: The RSI indicates a potential reversal from oversold conditions, while the 30-day moving average (MA30) at $102.3 is above the last close, signaling a potential upward trend. The 50-day moving average (MA50) at $96.97 is close to the current price, indicating a critical support level. Trade Plan: - Suggested Entry: $97.50 - Stop Loss: $94.00 (3.5% below entry) - Take Profit Targets: 1. $102.00 (5% ROI) 2. $106.00 (8.5% ROI) 3. $114.00 (17% ROI) This plan allows for a strong risk-reward ratio, capitalizing on the oversold condition and potential upward movement. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:17 AM
Actionable Trade Alert for $INCY: Market Context: $INCY is currently trading at $95.41, showing a bearish sentiment as indicated by an RSI of 34.41, suggesting that the stock is oversold. The price is also below both the 30-day moving average (MA30) of 102.28 and the 50-day moving average (MA50) of 96.54, reinforcing a downward trend. Directional Bias: Given the current RSI and the position relative to MAs, we anticipate a potential reversal or rebound. The 60-day high of 109.28 and low of 81.09 indicates a significant range, providing room for upward movement. Trade Plan: - Suggested Entry: $95.41 - Stop Loss: $92.00 (3.3% below entry) - Take Profit Targets: 1. TP1: $100.00 (4.2% gain) 2. TP2: $105.00 (10.0% gain) 3. TP3: $112.00 (17.4% gain) This trade setup offers a risk-reward ratio that aligns with our goal of achieving at least a 17% ROI on TP3. Monitor closely for price action around the targets. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 14 at 6:27 PM
$IFRX $MLTX $INCY $BIIB https://www.dermatologytimes.com/view/global-hidradenitis-suppurativa-atlas-ghisa-finds-hs-affects-1-of-the-world-s-population?utm_content=361519958&utm_medium=social&utm_source=twitter&hss_channel=tw-55642575 “Our analysis confirms that HS affects far more people than previously thought, and this has profound implications for awareness, screening, and resource allocation,” she said.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:10 PM
Actionable Trade Alert for $INCY: Market Context: $INCY is currently trading at $95.68, with a Relative Strength Index (RSI) of 35.19 indicating it is oversold. The stock is below its 30-day moving average (MA30) of 102.17 and slightly above its 50-day moving average (MA50) of 96.35, suggesting potential upward momentum as it approaches the 50-day MA. Directional Bias: Given the RSI and proximity to the 60-day low of 81.09, there is a bullish bias for a rebound towards the higher end of the recent trading range. Trade Plan: - Suggested Entry: $95.68 - Stop Loss: $92.00 (3.5% below entry) - Take Profit Targets: - TP1: $100.00 (4.8% gain) - TP2: $105.00 (9.6% gain) - TP3: $112.00 (17.0% gain) This plan provides a clear risk-reward ratio with a potential 17% ROI on TP3. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BiotechValues
BiotechValues Dec. 10 at 3:00 PM
$BCAB all comes down to next week. $INCY as top partner prediction by GROK. (ChatGPT's $EXEL pick has R/D day today, so it's not them). $INCY has historically done Dec deals and was talking about deals last week at investor conferences.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:14 AM
Actionable Trade Alert for $INCY: Market Context: $INCY closed at $95.16, indicating a potential for upward movement after hitting a low RSI of 31.03, which suggests oversold conditions. The stock is trading below both the 30-day MA (101.87) and the 50-day MA (95.96), indicating bearish sentiment but also potential for a reversal. Directional Bias: Given the RSI is below 30, we may see a rebound. The recent 60-day high of 109.28 provides a clear target for bullish momentum, while the 60-day low of 81.09 indicates strong support. Trade Plan: - Suggested Entry: $95.50 (slightly above the last close to confirm upward momentum) - Stop Loss: $91.75 (approximately 3.7% below entry) - Take Profit Targets: 1. $100.00 (5.2% gain) 2. $105.00 (10.0% gain) 3. $111.00 (16.4% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply